• S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

  • Aug 7 2024
  • Length: 11 mins
  • Podcast

S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

Listen for free

View show details

  • Summary

  • In the second half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean, Matt discusses the implications of his key EASL Congress takeaways for PharmaNest.

    Matt starts this discussion with a simple question: Will biopsy-based analyses become part of a surrogate endpoint? As he points out, they are not today, and creating the necessary data might require a significant effort. If not, they are unlikely to remain relevant to the large, Phase 3 trials. Regardless of the answer to this question, Matt believes digital pathology will still be important in pre-clinical work and other efforts to define underlying liver structures and faults better. Also, he notes, digital pathology is valuable in an array of other liver diseases and in non-hepatological markets, notably including pathology. One way or another, he is confident PharmaNest will continue to make contributions to hepatology and grow as a business.
    Show more Show less
activate_WEBCRO358_DT_T2
Physical Illness & Disease Hygiene & Healthy Living Natural History
Show more Show less

What listeners say about S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available